Core Viewpoint - The Hong Kong Stock Connect innovative drug sector has experienced a continuous adjustment for six days, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a decline of 0.75% and a trading volume of 200 million [1]. Group 1: Market Performance - The innovative drug ETF (520880) is fully invested in innovative drug R&D companies and has recently attracted significant capital inflows, indicating a potential opportunity for investment in innovative drugs [3][12]. - The leading pharmaceutical companies are expected to have promising earnings forecasts for 2025, which could lead to valuation recovery opportunities [3][12]. - The ETF has seen a recent increase in fund size to 2.348 billion, with the number of shares reaching 4.382 billion, both hitting new highs since its listing [4][10]. Group 2: Long-term Outlook - The core logic of the Hong Kong Stock Connect innovative drug sector remains solid, with expectations of a total overseas licensing amount for innovative drugs reaching 135.7 billion in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][12]. - The National Medical Products Administration (NMPA) is expected to approve 76 innovative drugs in 2025, leading the world in approvals, and will continue to optimize the review and approval process for innovative drugs [3][12]. - Investment strategies from Zhongtai International and Guosen Securities recommend continued focus on the innovative drug sector for 2026 [3][12]. Group 3: ETF Characteristics - The ETF exclusively covers innovative drug R&D companies, excluding CXO, and has a significant concentration in leading companies, with the top ten innovative drug companies accounting for over 73% of the weight [5][12]. - The ETF employs a strategy to reduce the weight of less liquid component stocks, effectively managing tail risks [6][12]. - The ETF's tracking index has a notable advantage with a high concentration of leading companies, enhancing its investment value [7][12].